Zentalis Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Zentalis Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 36.00K shares.
- Zentalis Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 21.00K shares.
- Zentalis Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares.
- Zentalis Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares.
- Zentalis Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 0.00 shares, a 100.00% decline from fiscal 2024.
- Zentalis Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 687.00 shares, a 98.74% decline from fiscal 2023.
- Zentalis Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 54.32K shares, a 55.50% decline from fiscal 2022.
- Zentalis Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 122.08K shares, a 47.53% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 36.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 57.00K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 21.00K shares 10-Q · filed 2026-05-12 | 21.00K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 0.00 shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -313.00 shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -313.00 shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-14 | 687.00 shares derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | -313.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | 687.00 shares 10-K · filed 2025-03-26 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 1.02K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 1.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | 3.82K shares derived: sum of 4 quarters · filed 2024-08-09 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-07 | 54.32K shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 24.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 54.32K shares 10-K · filed 2024-02-27 |
| 2023-09-30 | 2.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 116.28K shares derived: sum of 4 quarters · filed 2023-11-06 |
| 2023-06-30 | 51.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 131.58K shares derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-10 | 88.88K shares derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | 61.98K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | 122.08K shares 10-K · filed 2023-03-01 |
| 2022-09-30 | 18.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 192.78K shares derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | 8.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | |
| 2022-03-31 | 33.20K shares 10-Q · filed 2022-05-05 | |
| 2021-12-31 | 132.68K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | 232.68K shares 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |